Journals listed in Web of Science and JCR receive many submissions and desk reject a large share. A section-by-section audit by a PhD reviewer in your area shows what to fix first.
Manuscript Auditing →01Impact factor
Impact factor of Endocrine Metabolic & Immune Disorders - Drug Targets (2026)
The impact factor shown here is the 2-year mean citedness: citations received in a year by the papers Endocrine Metabolic & Immune Disorders - Drug Targets published in the two previous years, divided by the number of those papers. That is the same formula as the Journal Impact Factor, applied to the open citation data of OpenAlex. The journal is listed in JCR 2024, so it also has an official Journal Impact Factor published by Clarivate, which can differ because it counts citations from Web of Science journals only.
Rank in its subject categories
- Pharmacology & Pharmacyrank 267 of 371 journals
- Endocrinology & Metabolismrank 154 of 203 journals
- Immunologyrank 151 of 189 journals
Ranks here compare journals of the same Web of Science category in our data by 2-year citedness; they are not the official JCR rank.
Quartile of Endocrine Metabolic & Immune Disorders - Drug Targets
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Endocrine Metabolic & Immune Disorders - Drug Targets is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Citations and papers per year
02Review time
Review time of Endocrine Metabolic & Immune Disorders - Drug Targets
Each paper took a different time. The green box holds the middle half of the papers and the dark line is the median. Plan with the whole spread, not only the median.
Half of the research articles Endocrine Metabolic & Immune Disorders - Drug Targets published between Feb 2026 and Sep 2026 were accepted within 96 days of submission, and the middle half took between 78 and 118 days. This time includes peer review and any revision rounds. Papers that were rejected are not counted, because only published papers carry these dates.
In Pharmacology & Pharmacy, Endocrine Metabolic & Immune Disorders - Drug Targets ranks 57 of 157 journals by review time (1 = fastest). See the fastest-review journals in Pharmacology & Pharmacy →
03Fee waivers
APC waivers and discounts for Endocrine Metabolic & Immune Disorders - Drug Targets
Endocrine Metabolic & Immune Disorders - Drug Targets follows the waiver policy of its publisher, Bentham Science: 50% discount for corresponding authors in countries on Bentham's low-income list. Only the corresponding author's affiliation counts. Co-authors from other countries do not change the waiver.
Waivers apply to fully open access journals. If Endocrine Metabolic & Immune Disorders - Drug Targets is a hybrid journal, you can publish without any fee through the subscription route.
Checking the waiver rules for your country…
Retractions and research integrity at Endocrine Metabolic & Immune Disorders - Drug Targets
Most common reasons (a retraction can have several):
Endocrine Metabolic & Immune Disorders - Drug Targets has 1 retracted paper in the Retraction Watch database, the latest in Mar 2010. A retraction count is not a verdict on a journal: large journals publish more and journals that investigate actively retract more. The trend and the reasons tell you more than the number.
Submitting to Endocrine Metabolic & Immune Disorders - Drug Targets? See your rejection risk first.
Seven questions our reviewers ask in every audit, plus your abstract and the fit with this journal. Free, no sign-up, about 2 minutes.
04Indexing
Indexing of Endocrine Metabolic & Immune Disorders - Drug Targets
- ISSN
- 1871-5303
- eISSN
- 2212-3873
- Publisher
- Bentham Science Publishers
- Country
- U Arab Emirates
- Language
- English
- Scopus source type
- Journal
- Web of Science categories
- Endocrinology & Metabolism, Immunology, Pharmacology & Pharmacy
From the indexing lists used on ScholarsColab, updated 1 March 2026. Indexing can change: confirm on the Web of Science Master Journal List or the Scopus source list before submitting. Official Journal Impact Factors and JCR quartiles are published by Clarivate; the impact factor and quartile on this page are calculated from OpenAlex open data (see how the impact factor works).
05Reviewer comments
Reviewer comments and rejection reasons for Endocrine Metabolic & Immune Disorders - Drug Targets
No reviewer or editor comments have been shared for this journal yet. Did you submit here? Help other researchers by sharing the comments you received, anonymously.
Share reviewer comments for this journal →Across the reviewer comments researchers have shared with us, the points raised most often are figures, tables and equations (21%), literature and references (12%) and novelty and contribution (10%). Before you submit to Endocrine Metabolic & Immune Disorders - Drug Targets, a Manuscript Audit by a PhD reviewer in your area checks your paper against exactly these points.
Audit my paper before I submit →Not sure yet? Check if your paper is ready for this journal: free, no AI, under 5 secondsPreparing to submit here? Make sure reviewers don't stop at the issues they raise most often. A PhD reviewer in your area can audit your manuscript section by section, and we can convert it into the journal's LaTeX template.
06Journal Finder
Find the right journal for your paper
Is Endocrine Metabolic & Immune Disorders - Drug Targets right for your paper? Compare journals
Paste your title, keywords or abstract. See the journals that published the closest papers, with indexing, impact factor, review time and APC.
No AI or language model is used. Your words are matched against the titles of 156,503 real published journal papers, by our mentors and by other researchers (shown without names); journals are ranked by how many closely matching papers they published. Indexing comes from the SCIE, SSCI, AHCI, ESCI, Scopus and JCR 2024 lists, matched by journal name; the impact factor is calculated from OpenAlex open data, not the official Clarivate value, and no quartile is shown until the official JCR or SJR quartile can be; review time comes from the dates publishers deposit in Crossref (not every publisher deposits them). Always check a journal’s scope and current indexing before submitting.
07Questions
Frequently asked questions
How long is the review time of Endocrine Metabolic & Immune Disorders - Drug Targets?
Based on 185 research articles Endocrine Metabolic & Immune Disorders - Drug Targets published from Feb 2026 to Sep 2026, the median time from submission to acceptance was 96 days, and half of them were accepted between 78 and 118 days. After acceptance, papers appeared online after a median of 183 days. Source: received and accepted dates deposited by the publisher in Crossref, retrieved October 2026. Individual papers can take longer, especially with major revisions.
What is the impact factor of Endocrine Metabolic & Immune Disorders - Drug Targets?
Based on OpenAlex citation data (October 2026), the 2-year impact factor of Endocrine Metabolic & Immune Disorders - Drug Targets is 1.50: papers it published in the two previous years were cited 1.50 times on average in a year. The journal is listed in JCR 2024, so Clarivate also publishes an official Journal Impact Factor, which can differ.
What is the h-index of Endocrine Metabolic & Immune Disorders - Drug Targets?
The h-index of Endocrine Metabolic & Immune Disorders - Drug Targets is 67 (OpenAlex, October 2026): 67 of its papers have each been cited at least 67 times. Its i10-index is 728.
What is the quartile of Endocrine Metabolic & Immune Disorders - Drug Targets?
A journal's quartile (Q1 to Q4) is its position within a subject category: Q1 is the top quarter. The official quartiles are published by Clarivate in Journal Citation Reports (by Journal Impact Factor, in Web of Science categories) and by Scimago as the SJR quartile (in Scopus categories). Endocrine Metabolic & Immune Disorders - Drug Targets is listed in JCR 2024, so its JCR quartile is in Journal Citation Reports. It is indexed in Scopus, so Scimago shows its SJR quartile. ScholarsColab does not show a quartile until it can show the official one; the impact factor and rank above are calculated from open data.
Is Endocrine Metabolic & Immune Disorders - Drug Targets indexed in Scopus?
Yes. Endocrine Metabolic & Immune Disorders - Drug Targets appears in the Scopus list, according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Endocrine Metabolic & Immune Disorders - Drug Targets an SCIE journal?
Yes. Endocrine Metabolic & Immune Disorders - Drug Targets is listed in the Science Citation Index Expanded (SCIE), according to the indexing lists used on ScholarsColab (updated 1 March 2026). Always confirm the current status on the official list before submitting.
Is Endocrine Metabolic & Immune Disorders - Drug Targets in Journal Citation Reports (JCR)?
Yes. Endocrine Metabolic & Immune Disorders - Drug Targets is listed in JCR 2024, so it has a Journal Impact Factor. For the current impact factor and quartile, check Journal Citation Reports.
Does Endocrine Metabolic & Immune Disorders - Drug Targets offer an APC waiver?
Endocrine Metabolic & Immune Disorders - Drug Targets follows the policy of Bentham Science: 50% discount for corresponding authors in countries on Bentham's low-income list. Only the corresponding author's affiliation counts. Co-authors from other countries do not change the waiver. Rules verified 27 October 2026; confirm on the publisher's page.
Has Endocrine Metabolic & Immune Disorders - Drug Targets retracted papers?
Yes. The Retraction Watch database lists 1 retracted paper in Endocrine Metabolic & Immune Disorders - Drug Targets, 0 of them in the last 10 years; the most common reasons are duplication of/in article. A retraction count alone is not a verdict on a journal; look at the trend and the reasons. Data updated October 2026.
Want a PhD expert to choose the journal with you?
Our Journal Selection & Submission service shortlists up to 5 journals that match your manuscript, indexing requirement and target quartile, and handles the submission. If your paper was rejected before, a Manuscript Audit shows what to fix first.
Not sure yet? Check your manuscript for this journal, free · How the process works
Popular journals
- The Lancet
- Nature
- Science
- PLoS ONE
- Scientific Reports
- Journal of the American Chemical Society
- Physics Letters A
- BMJ
- Journal of Alloys and Compounds
- Nucleic Acids Research
- Biophysical Journal
- International Journal of Biological Macromolecules
- Journal of Molecular Structure
- Zootaxa
- Chemical Engineering Journal
- Medicine
- Astrophysical Journal
- Energies
- Chemosphere
- Journal of Physical Chemistry
Browse all journals: indexing, impact factor and reviewer comments →